Clinical Trial Update: LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating LP-168 in combination with obinutuzumab for chronic lymphocytic leukemia/small lymphocytic lymphoma and related variants is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• LP-168 (LP-168)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Zulfa Omer | Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma | Phase 2 | Status: RECRUITING